TerminatedNot Applicable

carDIo-ttranSSfOrm nucLEar Imaging Study

Stopped: Rolled over into another study

United States4 participantsStarted 2022-01-19

Plain-language summary

The investigators will evaluate the change in myocardial uptake of 99m-technetium pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in the CARDIO-TTRansform clinical trial (NCT04136171).

Who can participate

Age range60 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who were screened and eligible to be enrolled or have been already enrolled in the CARDIO-TTRansform randomized clinical trial (NCT04136171) and have a baseline 99m-technetium pyrophosphate planar and SPECT imaging done within 12 months prior to screening for CARDIO-TTRansform. * Patients have to meet the inclusion and exclusion criteria of CARDIO-TTRansform trial to be enrolled. * Patient willing to consent for the study and undergo the study procedures. Exclusion Criteria: * None

What they're measuring

Primary outcome

Timeframe: 120-140 weeks

Trial details

NCT IDNCT05259072

SponsorOregon Health and Science University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-30

View on ClinicalTrials.gov More Amyloidosis trials